The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | New trends in the management of leukemia
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Robin Foà, MD, from Sapienza University, Rome, Italy, summarises major advances, including the development of immunotherapy and targeted therapies, in the treatment of patients with hematological malignancies. Discussed examples include the introduction of B-cell receptor (BCR) kinase inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML).
